Wobble Base®
BioResearch

WB Fragile X Syndrome [Conventional PCR amplification and gel electrophoresis technique]

OUR CERTIFICATIONS

Our certifications
✓ ISO 13486:2016 certified
✓ ISO 9001: 2015 certified
✓ DPIIT (Govt. of India) certified
✓ Institutional Biosafety Committee (DBT)
✓ MSME Registered
✓ Trademark Registered with Trade Mark, Registry, Govt. of India

CONTACT

PHONE:
+91-6353339602

WEBSITE:
Wobblebase.in

EMAIL:
support@wobblebase.in

GRANTS/AWARDS

- ✓ Biotechnology Ignition Grant Award-2013
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Phase-1 Grant -2015;
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Phase 2 Grant-2017
- ✓ Grand Challenge Explorations- Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Grant-2017
- ✓ DBS-NUS Social Venture Challenge Asia 2017 Finalist.
- ✓ BIRAC (Dept. of Biotechnology) Pre- Accelerator MedTech Challenge Grant-2021
- ✓ Fastest Growing Indian Company Award (2019) – International Achievers Conference, Bangkok
- ✓ Small Business Innovation Research Initiative (SBIRI) (2013) – Dept. of Science and Tech., Govt. of India.

INTRODUCTION

- Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism. This x-linked disorder is caused by a full mutation expansion (>200 CGG repeats) within the FMR1 gene

- WobbleBase Fragile X syndrome Conventional PCR Kit is an in vitro diagnostic device that uses polymerase chain reaction (PCR) and capillary electrophoresis to detect and identify the number of cytosine-guanine-guanine (CGG) repeats in the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene using genomic DNA isolated from peripheral whole blood specimens.

- It is solely intended as an aid in the postnatal diagnosis of fragile X syndrome, and fragile X-associated disorders [i.e., fragile X-associated tremor/ataxia syndrome (FXTAS) or fragile X-associated primary ovarian insufficiency (FXPOI)], and for carrier testing in adults of reproductive age.

KEY FEATURES

- Precision and Reliability: Trust in our meticulously crafted reagents designed to deliver consistent and reliable results every time. With Conventional PCR amplification, we ensure unparalleled accuracy in identifying Fragile X Syndrome.

- Efficiency Redefined: Streamline your laboratory processes with our user-friendly reagents. Experience swift turnaround times without compromising on quality, allowing you to focus on what truly matters – patient care.

- Versatility: Whether you're a seasoned researcher or a novice in the field, our reagents cater to all skill levels. Seamlessly integrate them into your workflow for hassle-free Fragile X Syndrome detection.

- Cost-Effective Solution: Say goodbye to exorbitant expenses associated with complex detection methods. Our reagents offer a cost-effective alternative without compromising on the quality of results.

- Comprehensive Support: We prioritize your success. Count on our dedicated support team to assist you at every step of the

WB Fragile X Syndrome [Conventional PCR amplification and gel electrophoresis technique]

✓ TATA Health Fund (Phase 1 - Biosafety) – 2024

Your thinking partner in science

way, ensuring a seamless experience from purchase to implementation.

SPECIFICATIONS

Technology	Conventional PCR amplification and gel electrophoresis technique
Type of Analysis	Qualitative
Target Sequence	Expansions as well as deletions of the repeating CGG·CCG DNA sequence in the 5′-untranslated region of the FMR1 gene on the X chromosome
Reporting Units	Detected, Not detected or Inconclusive
Controls	Inhibition and extraction control, negative control, positive control
Validated specimen	Whole blood
Storage	-20 ± 5 °C
Instrument	Compatible with a wide range of conventional PCR devices

CATALOG NUMBER	PRODUCT INFORMATION	CONTENTS
FXG/WBB/50	WB Fragile X syndrome Conventional PCR Kit	50 reactions
FXG/WBB/100	WB Fragile X syndrome Conventional PCR Kit	100 reactions